LLY Forensic analysis

Trading Setup & Entry Strategy

• >Entry Strategy: LLY is in a powerful uptrend. Do not chase the current $1021.41 level. Enter 30% position at $990.00 (retest of 10-day SMA), add 40% at $940.00 (retest of 50-day SMA support), and final 30% at $924.00 (200-day SMA confluence).
• >Stop Loss: $890.00 (HARD). A daily close below the 200-day SMA invalidates the bullish thesis and signals a trend reversal.
• >Take Profit: $1055.00 (initial target/Bollinger Upper Band), followed by $1125.00 (extension target).
• >Risk/Reward: Targeting ~1:2.8 based on the entry zone and stop loss.

Executive Summary

Eli Lilly (LLY) continues to dominate the GLP-1 market, with Q1 2026 revenue of $19.79B (+56% YoY). Despite regulatory headwinds (IRA pricing, 340B litigation), the momentum remains strongly bullish. Current Price: $1021.41. Thesis: Growth is pricing in significant capacity expansion; focus on execution in the Medicare bridge program.

Recent Material Events (8-K Analysis)

Recent 8-K filings (April/May 2026) focus on routine corporate governance and financial disclosures, confirming no immediate material disruption to the drug pipeline despite ongoing legal battles regarding the 340B program and insulin pricing.

Insider Trading Activity

Recent Form 4 filings (May 19, 2026) indicate ongoing activity. Investors should monitor for consistent selling patterns, which are typical for executives utilizing pre-planned Rule 10b5-1 sales programs (e.g., Hakim, Yuffa, Jonsson plans disclosed in Q1).

Financial Health

• >Revenue Quality: Strong. Net product revenue of $18.45B dominates total revenue.
• >Cash Flow: Operating cash flow of $5.33B in Q1, though high capex for manufacturing expansion persists.
• >Balance Sheet: $5.28B in cash vs $43.4B in total debt. Liquidity remains robust for M&A and R&D.

Forensic Accounting Flags

[WARN]SBC/Dilution: Stock-based compensation ($161M) is managed, but high acquisition-related IPR&D charges ($584M) require careful modeling of future intangible amortization. [CRIT] Legal Contingencies: The ongoing 340B litigation and Supreme Court potential review represent a non-quantifiable tail risk.

Technical Analysis & Trade Timing

• >Momentum: The stock is currently 10.54% above the 200-day SMA, showing significant strength. RSI at 62.21 suggests room for upside before hitting overbought status (>70).
• >Trend: BULLISH_UPTREND. MACD is positive.
• >Reconciliation: While valuation is stretched (high growth expectations), the trend is undeniably dominant. We favor a 'buy on dip' approach to respect the momentum while maintaining a hard stop below support levels.

Short-Term Trading Strategy (2-5 Days)

• >Timeframe: Swing Trade (2–5 Days)
• >Position Size: 3% of portfolio.
• >Risk/Reward: Target R/R 1:2.5.
• >Catalyst: Monitor for any news regarding Medicare Part D drug price negotiations or competitor trial data (e.g., Viking Therapeutics).